Últimas noticias sobre Exscientia (NASDAQ:EXAI) Bolsa

Exscientia

Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.

Exscientia Plc - American Depositary Shares

Exscientia PLC

Exail Technologies SA

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price ta...

Morgan Stanley Remains a Hold on Exscientia Plc (EXAI)

Exscientia Plc (EXAI) has released an update. Exscientia plc has entered into a definitive agreement for acquisition by Recursion Pharmaceuticals, ...

Exscientia Set for Strategic Acquisition by Recursion

Recursion, Exscientia seek support for merger ahead of special meeting

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Exscientia Plc (EXAI – Research Report) today and set a price target of $5.70. Th...

Morgan Stanley Reaffirms Their Hold Rating on Exscientia Plc (EXAI)

Exscientia to receive $15M in milestones for Sanofi collaboration

Morgan Stanley Sticks to Its Hold Rating for Exscientia Plc (EXAI)

Exscientia Plc (EXAI) has released an update. Exscientia Plc has announced a key amendment to its transaction agreement with Recursion Pharmaceutic...

Exscientia Plc Enhances Board Collaboration with Recursion

Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Re...

Recursion, Exscientia shareholders approve proposed combination

Exscientia Plc (EXAI) has released an update. Shareholders of Recursion and Exscientia have overwhelmingly approved a merger, expected to be finali...

Recursion and Exscientia Merger Approved by Shareholders

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price target of ...

Barclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)

EXAI

NVDA

RXRX

Press Releases

Latest Updates of Viva Biotech's Portfolio Companies

General

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Exscientia Business Update for Second Quarter and First Half 2024

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Opinion

AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

News

Health Care

Recursion and Exscientia Shareholders Approve the Proposed Combination

AVAI

BLFY

GEHC

RLYB

TWST

Abivax

AnaptysBio

Annexon

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Avid Bioservices

Cargo Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Erasca

Humacyte

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Replimune Group

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Stoke Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Comments

Exscientia

Noticias

Últimas noticias sobre Exscientia (NASDAQ:EXAI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL